NCT06364774View on ClinicalTrials.gov

ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 14, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Beta-Thalassemia
Interventions
BIOLOGICAL

ALS20

novel lentiviral vector ALS20

Trial Locations (1)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
lead

Children's Hospital of Philadelphia

OTHER